Myeloproliferative neoplasms.
The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy remains a challenge. Although new drugs are being developed, treatment at present is predominantly with agents that have been in use for many years. An understanding of the need to control the thrombotic risk has, however, led to improved survival rates such that ET and PV can be seen as chronic diseases.
['Publicover|Amy|A|', 'Medd|Patrick|P|']
D006400:Hematocrit D006801:Humans D053614:Janus Kinase 2 D009154:Mutation D011087:Polycythemia Vera D055728:Primary Myelofibrosis D011379:Prognosis D013920:Thrombocythemia, Essential
myeloproliferative JAK2 myelofibrosis polycythaemia thrombocytosis